May 7, 2021
Xcenda is a key supporter of ISPOR 2021
Join Xcenda at ISPOR 2021 starting on Monday, May 17 through Thursday, May 20. Meet (virtually) with our commercialization and scientific consultants at this year's event where Xcenda is a "key supporter" of the conference.
As leaders in innovation for over 25 years, our creative, scientific minds of Xcenda have been delivering access “firsts”. We proudly launched the first reimbursement field team, developed the first outcomes analyzer, as well as the concept of the product value proposition—all by staying focused on being patient-first. Connect with us at this virtual event and we'll help you effectively navigate today’s complex healthcare landscape and help you deliver the most distinctive body of evidence that demonstrates your value story.
Start a conversation
Meet with Xcenda
We’re committed to helping you find solutions to maximize access to your product. From generating evidence that payers demand to value assessment frameworks consulting, turn to Xcenda for innovative solutions to prove the value of your therapy.
Meet with Mike Eaddy, Vice President of Scientific Consulting, and Patricia Wolfangel, Vice President of Customer Engagement, to discuss strategies and solutions for your product.
Podium presentation
Patient-Relevance of Endpoints Other Than Overall Survival (non-OS endpoints) in Oncology Health Technology Assessments by the Federal Joint Committee (G-BA) in Germany
Authors:
- Werner Kulp (presenter)
- Vishwas Agashe
- Nikolas Couybes
- Jason Ward
Xcenda continues excellence in innovative research
Join us at the ISPOR 2021 virtual conference as we are proud to present the following reach.
| Poster title | Xcenda authors |
|---|---|
| Budget Impact of reSET-O With Treatment-as-Usual (TAU) vs TAU Alone For The Treatment of Opioid Use Disorder (OUD) Over 5 Years |
Danmeng Huang, Charley Hallock, Lorie Mody |
| Evaluation of Artificial Intelligence within DistillerSR Software As a Second Reviewer for a Systematic Literature Review | Aishani Patel, Charley Hallock, Nicole Fusco, Sarah Cadarette, Lorie Mody |
| Conceptualization and novel budget impact analysis framework for treatments of myasthenia gravis | Danmeng
Huang, David Campbell |
| Current
Utilization and Perceptions of Value Assessment Frameworks Among United
States Payers |
Allie Choate, Annie Yan, Robin Tan, Linnea
Tennant |
| The Evolution of Payer Perceptions of ICER | Seth Cook, Anne Loos, Robin Tan, Linnea
Tennant |
| Potential Drug-Drug Interactions to Novel Anti-Androgen Therapies
Among Non-Metastatic Castration-Resistant Prostate Cancer Patients |
Andrew
Gaiser |